Xtandi Evrópusambandið - íslenska - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Noritren Tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

noritren tafla 10 mg

h. lundbeck a/s* - nortriptylinum hýdróklóríð - tafla - 10 mg

Noritren Tafla 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

noritren tafla 25 mg

h. lundbeck a/s* - nortriptylinum hýdróklóríð - tafla - 25 mg

Noritren Tafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

noritren tafla 50 mg

h. lundbeck a/s* - nortriptylinum hýdróklóríð - tafla - 50 mg